What is the recommended management for hepatorenal syndrome in cirrhotic patients?

Management of Hepatorenal Syndrome in Cirrhotic Patients

Terlipressin plus albumin is the first-line treatment for HRS-AKI (Type 1 HRS), with terlipressin 1 mg IV every 4-6 hours plus albumin 1 g/kg (maximum 100 g) on day 1, followed by 20-40 g/day, escalating terlipressin to 2 mg every 4 hours if creatinine fails to decrease by ≥25% after 3 days. 1, 2

Diagnostic Confirmation Before Treatment

Before initiating therapy, you must confirm HRS-AKI by meeting all diagnostic criteria: 1, 2

• Cirrhosis with ascites plus serum creatinine >1.5 mg/dL (or AKI stage ≥2) 1
• No improvement after 2 consecutive days of diuretic withdrawal and albumin volume expansion (1 g/kg for 2 days) 1, 2
• Absence of shock, nephrotoxic drug exposure, and structural kidney disease (proteinuria <0.5 g/day, no microhematuria <50 RBCs/HPF, normal renal ultrasound) 1, 2
• Perform diagnostic paracentesis immediately to exclude spontaneous bacterial peritonitis, which precipitates HRS in approximately 30% of cases 1, 2

First-Line Pharmacologic Treatment: Terlipressin + Albumin

Initial Dosing Protocol

Start terlipressin 1 mg IV bolus every 4-6 hours (equivalent to 0.85 mg terlipressin acetate) plus albumin 1 g/kg (maximum 100 g) on day 1, then 20-40 g/day thereafter. 1, 2, 3

Dose escalation strategy: If serum creatinine has not fallen ≥25% by day 3-4, increase terlipressin to 2 mg IV every 4 hours (maximum 12 mg/day). 1, 2

Alternative continuous infusion: Terlipressin 2 mg/day by continuous IV infusion reduces total daily dose and adverse events compared with bolus dosing. 1, 2

Treatment duration: Continue until serum creatinine ≤1.5 mg/dL on two consecutive measurements (≥2 hours apart) or for a maximum of 14 days; median time to response is 14 days. 1, 2

Predictors of Response

Favorable response is more likely with: 1, 2

• Baseline creatinine <3 mg/dL
• Bilirubin <10 mg/dL
• MAP increase ≥5 mmHg during therapy
• Lower MELD score and Child-Pugh <13
• Younger age

Absolute Contraindications to Terlipressin

Do not use terlipressin in patients with: 1, 2

• Active coronary, peripheral, or mesenteric ischemia
• Known ischemic heart disease (use midodrine/octreotide/albumin instead)
• Obtain baseline electrocardiogram before initiation 1, 2

Expected Hemodynamic Changes

Monitor for: 1, 3

• Heart rate decrease of approximately 10 beats/minute 1, 3
• MAP increase of approximately 16.2 mmHg (maximum effect at 1.2-2 hours post-dose) 3
• Central venous pressure (when available) to guide fluid balance 1, 2

Second-Line Treatment: Norepinephrine + Albumin

When terlipressin is unavailable or contraindicated, use norepinephrine 0.5-3 mg/hour continuous IV infusion plus albumin. 1, 2

Critical requirements: 1, 2

• ICU-level monitoring with central venous access (peripheral administration risks tissue necrosis)
• Titrate every 4 hours to raise MAP by 10-15 mmHg
• Equally effective as terlipressin (83% success rate in pilot studies) 1, 2

Third-Line Treatment: Midodrine + Octreotide + Albumin

Reserve this regimen only when terlipressin and norepinephrine are unavailable, as it achieves HRS reversal in only 28-29% versus 70% with terlipressin. 1, 2

Dosing: 1, 2

• Midodrine 7.5 mg orally three times daily, titrated up to 12.5 mg three times daily
• Octreotide 100-200 μg subcutaneously three times daily
• Albumin 10-20 g IV daily for up to 20 days

Advantage: Can be administered outside ICU and even at home. 1, 2

Preferred in ischemic heart disease: This is the safest vasoconstrictor regimen for patients with known coronary disease, as terlipressin is absolutely contraindicated in this population. 1, 2

Monitoring During Vasoconstrictor Therapy

Check the following parameters: 1, 2

• Serum creatinine every 2-3 days to assess renal response
• Complete response: Creatinine ≤1.5 mg/dL on two occasions
• Partial response: Creatinine decrease ≥25% but still >1.5 mg/dL
• MAP target: Increase by 10-15 mmHg
• Urine output and serum sodium should rise with effective treatment
• Watch for pulmonary edema, especially in patients with underlying cardiac dysfunction or cirrhotic cardiomyopathy 1, 2

Critical Management of Albumin in Volume Overload

If anasarca develops during treatment, discontinue albumin but continue vasoconstrictors. 2, 4

The 2024 AGA guideline emphasizes that albumin dosing must be individualized based on volume status rather than continued at a fixed dose once HRS-AKI is confirmed. 2, 4 Fixed albumin dosing without volume assessment can precipitate pulmonary edema (as demonstrated in the ATTIRE trial with aggressive dosing). 2

Vasoconstrictors remain the primary therapeutic agents and must be maintained for the full treatment course regardless of albumin discontinuation. 2, 4

Prevention of HRS

In Spontaneous Bacterial Peritonitis

Albumin 1.5 g/kg at SBP diagnosis, then 1 g/kg on day 3, reduces HRS incidence from 30% to 10% and mortality from 29% to 10%. 5, 1, 2

This is particularly effective in patients with baseline bilirubin ≥68 μmol/L (4 mg/dL) or creatinine ≥88 μmol/L (1 mg/dL). 5, 1

Other Prevention Strategies

• Norfloxacin 400 mg/day reduces HRS incidence in advanced cirrhosis 1, 2
• Pentoxifylline 400 mg three times daily prevents HRS in severe alcoholic hepatitis 1, 2
• Albumin 6-8 g per liter removed after large-volume paracentesis (>5 L) prevents post-paracentesis circulatory dysfunction 1, 2
• Antibiotic prophylaxis for 7 days after gastrointestinal bleeding 2

Transjugular Intrahepatic Portosystemic Shunt (TIPS)

TIPS is more suitable for Type 2 HRS (HRS-NAKI) because patients are clinically more stable; it improves renal function and ascites control. 1, 2, 6

Contraindications to TIPS: 2

• Severe hepatic dysfunction (bilirubin >5 mg/dL)
• High MELD score
• Significant renal dysfunction
• Cardiac failure
• Clinically significant hepatic encephalopathy

Small studies suggest TIPS may benefit Type 1 HRS, but its use is limited by advanced liver failure. 2, 6

Renal Replacement Therapy

Initiate RRT only as a bridge to liver transplantation based on clinical indications: 1, 2

• Refractory electrolyte/acid-base disturbances
• Refractory volume overload
• Symptomatic azotemia
• Worsening renal function despite vasoconstrictors

RRT should not be used as first-line therapy; outcomes in critically ill cirrhotic patients requiring RRT remain poor with high mortality. 2, 7

Definitive Treatment: Liver Transplantation

Liver transplantation is the only curative treatment for HRS-AKI, with expedited referral recommended for all Type 1 HRS patients. 1, 2, 6, 7

Post-transplant survival: Approximately 65% in Type 1 HRS 1, 2

Treatment of HRS before transplantation with vasoconstrictors may improve post-transplant outcomes. 1, 2

HRS reverses in approximately 75% of patients after liver transplantation alone (without combined liver-kidney transplant). 2

Management of Recurrent HRS

If HRS-AKI recurs after stopping therapy, repeat a course of vasoconstrictor treatment. 2

Vasoconstrictors and albumin are not recommended for HRS-NAKI (Type 2 HRS) outside AKI criteria, as recurrence after withdrawal is common and long-term outcome data are inconclusive. 2

Critical Pitfalls to Avoid

• Do not delay treatment: Early initiation of vasoconstrictors after HRS-AKI diagnosis improves outcomes, especially before progression to higher ACLF grades 2, 8
• Do not omit albumin initially: Albumin is essential for volume expansion and anti-inflammatory effects during the diagnostic phase and initial treatment 1, 2
• Do not persist with ineffective therapy: If creatinine fails to decrease ≥25% after 3-4 days despite dose escalation, consider alternative vasoconstrictors, RRT, or transplantation 1, 2
• Do not overlook precipitating factors: Always rule out and treat SBP, gastrointestinal bleeding, and discontinue nephrotoxic drugs 1, 2
• Do not re-initiate terlipressin after ischemic events, even if symptoms resolve, due to risk of recurrent ischemic complications 1, 2
• Each 1 mg/dL reduction in serum creatinine is associated with a 27% decrease in mortality risk, emphasizing the prognostic importance of treatment response 1, 2